Latest Regenerative February 3, 2026 News

The new registry aims to address evidence gaps and track long-term outcomes for orthobiologic treatments.
Lineage will evaluate the new gene-edited iPSC line for immune compatibility and manufacturing potential before pursuing exclusive rights with Factor Bioscience.
Long-term follow-up suggests ProTrans may help preserve insulin production, with results varying by dose.
The collaboration will assess whether robotic automation can help scale up cell therapy manufacturing while maintaining GMP standards.
The partnership aims to streamline production and quality testing of gene-edited hematopoietic stem cell therapies for HIV and rare diseases.

Stay updated on Regenerative Medicine